Abstract

PLAZOMICIN: AN AMINOGLYCOSIDE FOR NEXT GENERATION

Kiran R. Thorat*, Sayali C. Dudhal, Sachin K. Hodgar, Dhanashree R. Kad and Geetanjali S. Mehetre

ABSTRACT

The increasing resistance to commonly prescribed Antibiotics for Gram-negative bacteria is a serious global concern. Aminoglycosides are selectively active against gram negative bacteria; they act by inhibition of protein synthesis when administered orally or parentally. The common side effects associated with amino glycoside antibiotics are Nephrotoxicity and Ototoxicity. So to deal with such a resistance there two options, either to use toxic combination therapy of aminoglycosides with other antibiotics (e.g.: Vancomycin, beta lactams) to gain the synergistic effect or to discover next generation amino glycoside with less or no toxicities. An identification of structure with molecular formula C25H48N6O10 and 592.68 molecular weight from 490 analogous of Sisomicin with absence of 3’ OH and 4’-OH groups is named as “Plazomicin” or “ACHN-490” by Achaogen. Plazomicin is seen highly active against Multi drug resistant Enterobacteriaceae (MDR-EC), Aminoglycoside resistant Enterobacteriaceae (AR-EC), Enterobacteriaceae (EC), Tigecycline resistant (TR-EC). Colistin resistant (CR-CRE), Lack of nephrotoxicity or ototoxicity associated with plazomicin, Carbapenem resistant Enterobacteriaceae (CR-EC); make it drug of future in next generation aminoglycosides. In this review, I am trying to underlying discovery and development of plazomicin as newer antibiotic.

Keywords: Discovery and Development of Plazomicin, Multi-Drug Resistant Enterobacteriaceae, Aminoglycosides etc.